论文部分内容阅读
目的评价利肺片治疗糖尿病合并肺结核的疗效及安全性。方法将84例肺结核合并糖尿病患者分成治疗组和对照组,其中治疗组46例实施联合抗结核化疗方案并加服利肺片治疗,对照组38例只用联合抗结核化疗方案治疗。治疗1个月和3个月后将2组疗效、肝肾损害及血糖化血红蛋白A1(GHbA1)情况进行比较。结果 1个月后2组患者乏力、咳嗽咳痰和咯血完全缓解率治疗组显著高于对照组(P<0.05)。治疗3个月后病变显著吸收率治疗组显著高于对照组(P<0.05);治疗组有效率亦高于对照组(P<0.05)。结论利肺片辅助治疗可加速肺结核合并糖尿病患者乏力、咳嗽咳痰、咯血等临床症状的缓解,促进病变吸收,有效率高于单用联合抗结核化疗方案,用药安全。
Objective To evaluate the efficacy and safety of Liping Tablets in treating diabetic patients with pulmonary tuberculosis. Methods Eighty-four patients with pulmonary tuberculosis complicated with diabetes were divided into treatment group and control group, in which 46 patients in the treatment group were treated with anti-tuberculosis chemotherapy and were treated with obesity treatment and 38 patients in the control group were treated with combination anti-tuberculosis chemotherapy only. Two months after treatment and three months after treatment, liver and kidney damage and hemoglobin A1 (GHbA1) were compared. Results After 1 month, the two groups of patients with fatigue, cough and sputum and hemoptysis complete remission rate was significantly higher in the treatment group than in the control group (P <0.05). After 3 months of treatment, the significant rate of pathological changes in the treatment group was significantly higher than that in the control group (P <0.05). The effective rate of the treatment group was also higher than that of the control group (P <0.05). Conclusions LiLiPiao adjuvant therapy can accelerate the relief of clinical symptoms such as fatigue, cough, expectoration and hemoptysis in patients with pulmonary tuberculosis complicated with diabetes, and promote the absorption of the disease. The effective rate is higher than that of combined chemotherapy with anti-tuberculosis alone and the medication is safe.